Williams Peter | AMiner学者主页

PS1/1 Outcomes for women in phase 3 trials of long-acting cabotegravir + rilpivirine: pooled ATLAS and FLAIR week 48 results R Quercia, C Orkin, R D’Amico, J Mrus, S Wu, A Cutrell, K Chow, J Polli, D Margolis, P Williams, A de Ruiter, K Smith and W Spreen ViiV Healthcare, Brentford, UK Queen Mary University, London, UK ViiV Healthcare, Research Triangle Park, USA GlaxoSmithKline, Collegeville, USA GlaxoSmithKline, Mississauga, Canada Janssen Research & Development, Beerse, Belgium

2019HIV MEDICINE（2019）引用：2

引用

AI阅读

8Safety, Efficacy and Durability of Long-Acting CAB and RPV As Two-Drug IM Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 160 Results

D. Margolis,J. Gonzalez Garcia,H. Stellbrink,Y. Yazdanpanah, G. Richmond, G. Smith,K. Sutton,D. Dorey,F. Zhang,K. Smith,P. Williams,W. Spreen

2018JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2018）引用：5

引用

AI阅读

9Safety and Efficacy of Long-Acting Cab and Rpv As Two Drug Im Maintenance Therapy: Latte-2 Week 96 Results

J. Eron,D. Margolis,J. Gonzalez-Garcia,H-J Stellbrink,Y. Yazdanpanah,D. Podzamczer,T. Lutz,J. B. Angel,G. J. Richmond,B. Clotet,F. Gutierrez,L. Sloan,

2017JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2017）引用：1

引用

AI阅读

10An open-label multiple-dose phase 1 assessment of long-acting rilpivirine

I. McGowan,C. S. Dezzutti, A. Siegel, J. Engstrom, C. Shetler, N. Richardson-Harman,K. Abebe,D. Back,L. Else,D. Egan,S. Khoo,P. E. Williams,

2017JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2017）引用：1

引用

AI阅读

11Persistence of rilpivirine following single dose of long-acting injection

I. McGowan, A. Siegel, J. Engstrom, A. Nikiforov, K. Duffill,S. Edick,C. Mitchell,D. Back,L. Else,D. Egan,S. Khoo,P. Williams,

2016JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2016）引用：1

引用

AI阅读

12Cabotegravir plus rilpivirine as long-acting maintenance therapy: LATTE-2 week 48 results

D. Margolis,D. Podzamczer,H-J Stellbrink,T. Lutz,J. Angel, G. Richmond,B. Clotet,F. Gutierrez,L. Sloan,S. Griffith,M. St Clair,D. Dorey,

2016JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2016）引用：1

引用

AI阅读

13Pooled Week 96 Efficacy, Resistance and Safety Results from the Double-Blind, Randomised, Phase III Trials Comparing Rilpivirine (RPV, TMC278) Versus Efavirenz (EFV) in Treatment-Naïve, HIV-1-infected Adults

C. Orkin,C. Cohen,J-M Molina,I. Cassetti,P. Chetchotisakd,A. Lazzarin,F. Rhame,H. J. Stellbrink, L. Taisheng,H. Crauwels,L. Rimsky,S. Vanveggel,

Lost to follow-up, non-compliance, withdrew consent, ineligible to continue, sponsor's decision • Similar response rates for RPV and EFV were seen at Week 96, based on the ITT snapshot analysis (last viral load value in the Week 96 window (90-103 weeks) 95% adherence. Response rates were high and similar between treatment groups in patients with >95% reported adherence or baseline viral load ≤100K (Figure 4). Suboptimal adherence (≤95%) and baseline viral load >100K were associated with lower responses in both groups.

2012HIV MEDICINE（2012）引用：2

引用

AI阅读